Instrument Inactif

Communiqués XenoPort, Inc.

Actions

US98411C1009

Produits pharmaceutiques

Cours en clôture Nasdaq Autres places de cotation
- ^USD	-

23/05/16	Anthem : Les valeurs à suivre sur les marchés américains	RE
23/05/16	USA-Les valeurs à suivre à Wall Street	RE

Communiqués

05/07/16	XenoPort : Arbor Pharmaceuticals Completes Successful Tender Offer for Shares of XenoPort	BU
16/06/16	XenoPort : Arbor Pharmaceuticals and XenoPort Announce the Expiration of the HSR Act Waiting Period	BU
26/05/16	XENOPORT SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Xenoport, Inc. (XNPT) Over the Proposed Sale of the Company to Arbor Pharmaceuticals, LLC	BU
25/05/16	Levi & Korsinsky, LLP Announces Investigation Concerning Whether the Sale of XenoPort, Inc. to Arbor Pharmaceuticals, LLC for $7.03 Per Share is Fair to Shareholders -- XNPT	PR
25/05/16	Brower Piven Commences an Investigation into the Proposed Sale of XenoPort, Inc. and Encourages Investors to Contact the Firm for Additional Information	BU
24/05/16	Pomerantz LLP Investigates Claims That the Merger May Not Be in the Best Interest of Investors of XenoPort Inc. - XNPT	PR
24/05/16	Ryan & Maniskas, LLP : Announces Investigation of XenoPort, Inc.	PR
24/05/16	Brodsky & Smith, LLC Announces Investigation of The Board of Directors of XenoPort, Inc. -XNPT	PR
23/05/16	Harwood Feffer LLP : Announces Investigation of XenoPort, Inc.	PR
23/05/16	XENOPORT, INC. Former SEC Attorney Willie Briscoe and Powers Taylor LLP Believe the Acquisition by Arbor Pharmaceuticals, LLC May Be Unfair to Shareholders	BU
23/05/16	XENOPORT, INC. Rigrodsky & Long, P.A. Announces Investigation Of Buyout	BU
23/05/16	XENOPORT (XNPT) ALERT: Johnson & Weaver, LLP Launches an Investigation into the Fairness of Price and Process in Proposed Sale of XenoPort, Inc.; Are Shareholders Getting a Fair Price?	PR
23/05/16	XenoPort : Arbor Pharmaceuticals to Acquire XenoPort	BU
05/05/16	XenoPort : Reports First Quarter Financial Results	BU
26/04/16	XenoPort : to Release First Quarter Financial Results on May 5, 2016	BU
28/03/16	XenoPort : Dr. Reddy's Laboratories and XenoPort Enter into a U.S. Licensing Agreement for XP23829	PU
07/03/16	XenoPort : #StopMakingExcuses Awareness Campaign for Restless Legs Syndrome Launches During Sleep Awareness Week 2016	BU
01/03/16	XenoPort : to Present at the Cowen and Company 36th Annual Health Care Conference	BU
25/02/16	XenoPort : Reports Fourth Quarter and Year-End 2015 Financial Results	BU
16/02/16	XenoPort : to Release Fourth Quarter and Year-End Financial Results on February 25, 2016	BU
04/11/15	XenoPort : Reports Third Quarter Financial Results	BU
29/10/15	XenoPort : to Present at the Credit Suisse Healthcare Conference	BU
27/10/15	XenoPort : to Release Third Quarter Financial Results on November 4	BU
01/10/15	XenoPort : Announces Plan to Focus on its Growing HORIZANT Business and Names Vincent J. Angotti Chief Executive Officer and Director	BU
15/09/15	XenoPort : Announces Positive Phase 2 Study Results for XP23829 as a Potential Treatment for Patients with Psoriasis	BU